Increased peroxiredoxin 4 levels in patients with prediabetes compared to normal glucose tolerance subjects
Summary Background Peroxiredoxin 4 is a part of endogen antioxidant system and its levels are elevated in oxidative stress conditions. Its levels are positively associated with cardiovascular risk. The aim of this study was to compare serum peroxiredoxin 4 levels between obese subjects with prediabe...
Saved in:
| Published in | Clinical endocrinology (Oxford) Vol. 85; no. 4; pp. 551 - 555 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Blackwell Publishing Ltd
01.10.2016
Wiley Subscription Services, Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Summary
Background
Peroxiredoxin 4 is a part of endogen antioxidant system and its levels are elevated in oxidative stress conditions. Its levels are positively associated with cardiovascular risk. The aim of this study was to compare serum peroxiredoxin 4 levels between obese subjects with prediabetes and with normal glucose tolerance.
Methods
In this study, we included 80 patients with mean age 50·4 ± 10·6 years and divided them into two age and BMI‐matched groups – group 1 with obesity without glycaemic disturbances (n = 41) and group 2 with obesity and prediabetes (n = 39). Oral glucose tolerance test with measurement of immunoreactive insulin was performed in all participants, and the levels of peroxiredoxin 4 were measured using ELISA method.
Results
We found significantly higher levels of peroxiredoxin 4 in patients with prediabetes compared to controls (2851·2 ± 4576·6 pg/ml vs 1088·0 ± 753·3 pg/ml; P = 0·022). There was a mild but statistically significant correlation between peroxiredoxin 4 and weight (r = 0·232; P = 0·038), waist circumference (r = 0·239; P = 0·044), creatinine (r = 0·264; P = 0·019), liver enzymes (ASAT – r = 0·289; P = 0·019 and ALAT – r = 0·305; P = 0·07) and white blood cells count (r = 0·317; P = 0·005). There was no difference in peroxiredoxin 4 levels in patients with and without insulin resistance, as well as with and without metabolic syndrome (MetS), although the levels of peroxiredoxin 4 increased with the number of components of MetS.
Conclusions
The levels of peroxiredoxin 4 are higher in patients with prediabetes, but are similar in subjects with and without insulin resistance, which suggests that the main factor for its increased levels is hyperglycaemia and not insulin sensitivity state. |
|---|---|
| AbstractList | Summary
Background
Peroxiredoxin 4 is a part of endogen antioxidant system and its levels are elevated in oxidative stress conditions. Its levels are positively associated with cardiovascular risk. The aim of this study was to compare serum peroxiredoxin 4 levels between obese subjects with prediabetes and with normal glucose tolerance.
Methods
In this study, we included 80 patients with mean age 50·4 ± 10·6 years and divided them into two age and BMI‐matched groups – group 1 with obesity without glycaemic disturbances (n = 41) and group 2 with obesity and prediabetes (n = 39). Oral glucose tolerance test with measurement of immunoreactive insulin was performed in all participants, and the levels of peroxiredoxin 4 were measured using ELISA method.
Results
We found significantly higher levels of peroxiredoxin 4 in patients with prediabetes compared to controls (2851·2 ± 4576·6 pg/ml vs 1088·0 ± 753·3 pg/ml; P = 0·022). There was a mild but statistically significant correlation between peroxiredoxin 4 and weight (r = 0·232; P = 0·038), waist circumference (r = 0·239; P = 0·044), creatinine (r = 0·264; P = 0·019), liver enzymes (ASAT – r = 0·289; P = 0·019 and ALAT – r = 0·305; P = 0·07) and white blood cells count (r = 0·317; P = 0·005). There was no difference in peroxiredoxin 4 levels in patients with and without insulin resistance, as well as with and without metabolic syndrome (MetS), although the levels of peroxiredoxin 4 increased with the number of components of MetS.
Conclusions
The levels of peroxiredoxin 4 are higher in patients with prediabetes, but are similar in subjects with and without insulin resistance, which suggests that the main factor for its increased levels is hyperglycaemia and not insulin sensitivity state. Background Peroxiredoxin 4 is a part of endogen antioxidant system and its levels are elevated in oxidative stress conditions. Its levels are positively associated with cardiovascular risk. The aim of this study was to compare serum peroxiredoxin 4 levels between obese subjects with prediabetes and with normal glucose tolerance. Methods In this study, we included 80 patients with mean age 50.4 plus or minus 10.6 years and divided them into two age and BMI-matched groups - group 1 with obesity without glycaemic disturbances (n = 41) and group 2 with obesity and prediabetes (n = 39). Oral glucose tolerance test with measurement of immunoreactive insulin was performed in all participants, and the levels of peroxiredoxin 4 were measured using ELISA method. Results We found significantly higher levels of peroxiredoxin 4 in patients with prediabetes compared to controls (2851.2 plus or minus 4576.6 pg/ml vs 1088.0 plus or minus 753.3 pg/ml; P = 0.022). There was a mild but statistically significant correlation between peroxiredoxin 4 and weight (r = 0.232; P = 0.038), waist circumference (r = 0.239; P = 0.044), creatinine (r = 0.264; P = 0.019), liver enzymes (ASAT - r = 0.289; P = 0.019 and ALAT - r = 0.305; P = 0.07) and white blood cells count (r = 0.317; P = 0.005). There was no difference in peroxiredoxin 4 levels in patients with and without insulin resistance, as well as with and without metabolic syndrome (MetS), although the levels of peroxiredoxin 4 increased with the number of components of MetS. Conclusions The levels of peroxiredoxin 4 are higher in patients with prediabetes, but are similar in subjects with and without insulin resistance, which suggests that the main factor for its increased levels is hyperglycaemia and not insulin sensitivity state. Peroxiredoxin 4 is a part of endogen antioxidant system and its levels are elevated in oxidative stress conditions. Its levels are positively associated with cardiovascular risk. The aim of this study was to compare serum peroxiredoxin 4 levels between obese subjects with prediabetes and with normal glucose tolerance.BACKGROUNDPeroxiredoxin 4 is a part of endogen antioxidant system and its levels are elevated in oxidative stress conditions. Its levels are positively associated with cardiovascular risk. The aim of this study was to compare serum peroxiredoxin 4 levels between obese subjects with prediabetes and with normal glucose tolerance.In this study, we included 80 patients with mean age 50·4 ± 10·6 years and divided them into two age and BMI-matched groups - group 1 with obesity without glycaemic disturbances (n = 41) and group 2 with obesity and prediabetes (n = 39). Oral glucose tolerance test with measurement of immunoreactive insulin was performed in all participants, and the levels of peroxiredoxin 4 were measured using ELISA method.METHODSIn this study, we included 80 patients with mean age 50·4 ± 10·6 years and divided them into two age and BMI-matched groups - group 1 with obesity without glycaemic disturbances (n = 41) and group 2 with obesity and prediabetes (n = 39). Oral glucose tolerance test with measurement of immunoreactive insulin was performed in all participants, and the levels of peroxiredoxin 4 were measured using ELISA method.We found significantly higher levels of peroxiredoxin 4 in patients with prediabetes compared to controls (2851·2 ± 4576·6 pg/ml vs 1088·0 ± 753·3 pg/ml; P = 0·022). There was a mild but statistically significant correlation between peroxiredoxin 4 and weight (r = 0·232; P = 0·038), waist circumference (r = 0·239; P = 0·044), creatinine (r = 0·264; P = 0·019), liver enzymes (ASAT - r = 0·289; P = 0·019 and ALAT - r = 0·305; P = 0·07) and white blood cells count (r = 0·317; P = 0·005). There was no difference in peroxiredoxin 4 levels in patients with and without insulin resistance, as well as with and without metabolic syndrome (MetS), although the levels of peroxiredoxin 4 increased with the number of components of MetS.RESULTSWe found significantly higher levels of peroxiredoxin 4 in patients with prediabetes compared to controls (2851·2 ± 4576·6 pg/ml vs 1088·0 ± 753·3 pg/ml; P = 0·022). There was a mild but statistically significant correlation between peroxiredoxin 4 and weight (r = 0·232; P = 0·038), waist circumference (r = 0·239; P = 0·044), creatinine (r = 0·264; P = 0·019), liver enzymes (ASAT - r = 0·289; P = 0·019 and ALAT - r = 0·305; P = 0·07) and white blood cells count (r = 0·317; P = 0·005). There was no difference in peroxiredoxin 4 levels in patients with and without insulin resistance, as well as with and without metabolic syndrome (MetS), although the levels of peroxiredoxin 4 increased with the number of components of MetS.The levels of peroxiredoxin 4 are higher in patients with prediabetes, but are similar in subjects with and without insulin resistance, which suggests that the main factor for its increased levels is hyperglycaemia and not insulin sensitivity state.CONCLUSIONSThe levels of peroxiredoxin 4 are higher in patients with prediabetes, but are similar in subjects with and without insulin resistance, which suggests that the main factor for its increased levels is hyperglycaemia and not insulin sensitivity state. Peroxiredoxin 4 is a part of endogen antioxidant system and its levels are elevated in oxidative stress conditions. Its levels are positively associated with cardiovascular risk. The aim of this study was to compare serum peroxiredoxin 4 levels between obese subjects with prediabetes and with normal glucose tolerance. In this study, we included 80 patients with mean age 50·4 ± 10·6 years and divided them into two age and BMI-matched groups - group 1 with obesity without glycaemic disturbances (n = 41) and group 2 with obesity and prediabetes (n = 39). Oral glucose tolerance test with measurement of immunoreactive insulin was performed in all participants, and the levels of peroxiredoxin 4 were measured using ELISA method. We found significantly higher levels of peroxiredoxin 4 in patients with prediabetes compared to controls (2851·2 ± 4576·6 pg/ml vs 1088·0 ± 753·3 pg/ml; P = 0·022). There was a mild but statistically significant correlation between peroxiredoxin 4 and weight (r = 0·232; P = 0·038), waist circumference (r = 0·239; P = 0·044), creatinine (r = 0·264; P = 0·019), liver enzymes (ASAT - r = 0·289; P = 0·019 and ALAT - r = 0·305; P = 0·07) and white blood cells count (r = 0·317; P = 0·005). There was no difference in peroxiredoxin 4 levels in patients with and without insulin resistance, as well as with and without metabolic syndrome (MetS), although the levels of peroxiredoxin 4 increased with the number of components of MetS. The levels of peroxiredoxin 4 are higher in patients with prediabetes, but are similar in subjects with and without insulin resistance, which suggests that the main factor for its increased levels is hyperglycaemia and not insulin sensitivity state. Summary Background Peroxiredoxin 4 is a part of endogen antioxidant system and its levels are elevated in oxidative stress conditions. Its levels are positively associated with cardiovascular risk. The aim of this study was to compare serum peroxiredoxin 4 levels between obese subjects with prediabetes and with normal glucose tolerance. Methods In this study, we included 80 patients with mean age 50·4 ± 10·6 years and divided them into two age and BMI-matched groups - group 1 with obesity without glycaemic disturbances (n = 41) and group 2 with obesity and prediabetes (n = 39). Oral glucose tolerance test with measurement of immunoreactive insulin was performed in all participants, and the levels of peroxiredoxin 4 were measured using ELISA method. Results We found significantly higher levels of peroxiredoxin 4 in patients with prediabetes compared to controls (2851·2 ± 4576·6 pg/ml vs 1088·0 ± 753·3 pg/ml; P = 0·022). There was a mild but statistically significant correlation between peroxiredoxin 4 and weight (r = 0·232; P = 0·038), waist circumference (r = 0·239; P = 0·044), creatinine (r = 0·264; P = 0·019), liver enzymes (ASAT - r = 0·289; P = 0·019 and ALAT - r = 0·305; P = 0·07) and white blood cells count (r = 0·317; P = 0·005). There was no difference in peroxiredoxin 4 levels in patients with and without insulin resistance, as well as with and without metabolic syndrome (MetS), although the levels of peroxiredoxin 4 increased with the number of components of MetS. Conclusions The levels of peroxiredoxin 4 are higher in patients with prediabetes, but are similar in subjects with and without insulin resistance, which suggests that the main factor for its increased levels is hyperglycaemia and not insulin sensitivity state. |
| Author | Assyov, Yavor Gateva, Antoaneta Kamenov, Zdravko Velikova, Tsvetelina |
| Author_xml | – sequence: 1 givenname: Antoaneta surname: Gateva fullname: Gateva, Antoaneta email: tony_gateva@yahoo.com, tony_gateva@yahoo.com organization: Clinic of Endocrinology, Department of Internal Medicine, University Hospital "Alexandrovska", Medical University, Sofia, Bulgaria – sequence: 2 givenname: Yavor surname: Assyov fullname: Assyov, Yavor organization: Clinic of Endocrinology, Department of Internal Medicine, University Hospital "Alexandrovska", Medical University, Sofia, Bulgaria – sequence: 3 givenname: Tsvetelina surname: Velikova fullname: Velikova, Tsvetelina organization: Laboratory of Clinical Immunology, Department of Clinical Laboratory and Clinical Immunology, University Hospital "St. Ivan Rilski", Medical University, Sofia, Bulgaria – sequence: 4 givenname: Zdravko surname: Kamenov fullname: Kamenov, Zdravko organization: Clinic of Endocrinology, Department of Internal Medicine, University Hospital "Alexandrovska", Medical University, Sofia, Bulgaria |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27303935$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkUtv1DAUhS1URKcDC_4AssQGFmn9iPNYoqF0KkrZgJDYWI5zA546drAd2v57XGami6pIeGFfW985ur7nCB047wChl5Qc07xONLhjyikXT9CC8koUjFXiAC0IJ6QgVVUeoqMYN4QQ0ZD6GTpkNSe85WKBrs6dDqAi9HiC4G9MgD7vDpfYwm-wEed6UsmASxFfm_QTTxkxqoMEEWs_TirfcfLY-TAqi3_YWfsI-cVCUE4DjnO3AZ3ic_R0UDbCi925RF8_nH5ZrYuLz2fnq3cXhS5ZmZtXQ193zUBEV9OybylRZUUAVFnWuWsQ0LK-FEoxWlLVa6IGPnDRik4r1jTAl-jN1ncK_tcMMcnRRA3WKgd-jpI2rG6alrXN_6C8JXXDRUZfP0A3fg4uf-SOYi0jVW5viV7tqLkboZdTMKMKt3I_8QycbAEdfIwBBqlNyvP1LgVlrKRE3mUqc6byb6ZZ8faBYm_6GLtzvzYWbv8NytXp5V5RbBUmJri5V6hwJaua10J-uzyT64_iE12z9_I7_wNeDr8b |
| CitedBy_id | crossref_primary_10_3390_molecules27196513 crossref_primary_10_1016_j_freeradbiomed_2024_12_015 crossref_primary_10_1016_j_bbrc_2018_12_021 crossref_primary_10_1080_13813455_2018_1479762 crossref_primary_10_1111_pin_12634 crossref_primary_10_1186_s12902_019_0358_3 crossref_primary_10_1155_2021_9949753 crossref_primary_10_1007_s40200_022_01127_8 crossref_primary_10_1016_j_trac_2017_01_011 |
| Cites_doi | 10.4067/S0034-98872014000900003 10.1371/journal.pone.0089719 10.1001/archinte.164.19.2147 10.2337/dc09-2328 10.1242/jcs.067843 10.1016/S0025-7753(01)72168-9 10.1001/jama.285.16.2109 10.2337/diacare.22.3.399 10.1016/S0140-6736(98)12131-1 10.1590/1414-431X20144142 10.1016/j.freeradbiomed.2007.12.005 10.1161/JAHA.112.002956 10.1007/s00125-014-3278-9 10.1016/j.jacc.2009.10.060 10.2337/diacare.28.11.2756 10.1161/01.CIR.102.1.42 10.2337/diacare.26.12.3320 10.1007/s12192-013-0442-y 10.1179/135100002125000352 10.2174/1381612043384664 10.1016/j.biocel.2006.07.001 10.2337/diacare.26.3.688 10.1089/ars.2010.3137 10.1074/jbc.M106585200 10.1016/S0968-0004(02)00003-8 10.1016/j.it.2003.10.013 |
| ContentType | Journal Article |
| Copyright | 2016 John Wiley & Sons Ltd 2016 John Wiley & Sons Ltd. Copyright © 2016 John Wiley & Sons Ltd |
| Copyright_xml | – notice: 2016 John Wiley & Sons Ltd – notice: 2016 John Wiley & Sons Ltd. – notice: Copyright © 2016 John Wiley & Sons Ltd |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP K9. NAPCQ 7X8 |
| DOI | 10.1111/cen.13135 |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Calcium & Calcified Tissue Abstracts MEDLINE - Academic |
| DatabaseTitleList | Calcium & Calcified Tissue Abstracts MEDLINE - Academic MEDLINE ProQuest Health & Medical Complete (Alumni) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2265 |
| EndPage | 555 |
| ExternalDocumentID | 4193562641 27303935 10_1111_cen_13135 CEN13135 ark_67375_WNG_HK5M1H2D_Z |
| Genre | article Journal Article |
| GrantInformation_xml | – fundername: Medical University‐Sofia, Medical Sciences Council funderid: 5272/30.07.2014/Contract 2 – C/2014 |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 08P 0R~ 10A 1OB 1OC 29B 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AAQQT AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFZJQ AHBTC AHEFC AHMBA AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M J5H K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MJL MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K REN RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7QP AAMMB AEFGJ AGXDD AIDQK AIDYY K9. NAPCQ 7X8 |
| ID | FETCH-LOGICAL-c4245-2afd7b8f05b714d910a460eea447039e5e92d45aa2141adc0af3f3595bca288e3 |
| IEDL.DBID | DR2 |
| ISSN | 0300-0664 1365-2265 |
| IngestDate | Wed Jul 30 11:26:01 EDT 2025 Fri Jul 11 11:58:43 EDT 2025 Wed Aug 13 11:25:18 EDT 2025 Wed Feb 19 02:00:09 EST 2025 Tue Jul 01 01:33:16 EDT 2025 Thu Apr 24 23:02:11 EDT 2025 Wed Jan 22 17:04:11 EST 2025 Wed Oct 30 09:50:38 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2016 John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4245-2afd7b8f05b714d910a460eea447039e5e92d45aa2141adc0af3f3595bca288e3 |
| Notes | ark:/67375/WNG-HK5M1H2D-Z istex:84B04C224E727692CCA295E74F8D76B4402ABB02 ArticleID:CEN13135 Medical University-Sofia, Medical Sciences Council - No. 5272/30.07.2014/Contract 2 - C/2014 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PMID | 27303935 |
| PQID | 1822920670 |
| PQPubID | 36523 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_1827889298 proquest_miscellaneous_1823907835 proquest_journals_1822920670 pubmed_primary_27303935 crossref_citationtrail_10_1111_cen_13135 crossref_primary_10_1111_cen_13135 wiley_primary_10_1111_cen_13135_CEN13135 istex_primary_ark_67375_WNG_HK5M1H2D_Z |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2016-10 October 2016 2016-10-00 2016-Oct 20161001 |
| PublicationDateYYYYMMDD | 2016-10-01 |
| PublicationDate_xml | – month: 10 year: 2016 text: 2016-10 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | Clinical endocrinology (Oxford) |
| PublicationTitleAlternate | Clin Endocrinol |
| PublicationYear | 2016 |
| Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
| References | Tavender, T.J. & Bulleid, N.J. (2010) Peroxiredoxin IV protects cells from oxidative stress by removing H2O2 produced during disulphide formation. Journal of Cell Science, 123, 2672-2679. El Eter, E., Al Masri, A., Habib, S., Al Zamil, H., Al Hersi, A., Al Hussein, F. & Al Omran, M. (2014) Novel links among peroxiredoxins, endothelial dysfunction, and severity of atherosclerosis in type 2 diabetic patients with peripheral atherosclerotic disease. Cell Stress and Chaperones, 19, 173-81. El Eter, E. & Al-Masri, A. (2015) Peroxiredoxin isoforms are associated with cardiovascular risk factors in type 2 diabetes mellitus. Brazilian Journal of Medical and Biological Research, 48, 465-469. Arancibia, C., Galgani, J., Valderas, J.P. et al. (2014) Evaluation of serum insulin levels after an oral glucose load for the diagnosis of insulin resistance. Revista Medica de Chile, 142, 1106-1112. Dandona, P., Aljada, A. & Bandyopadhyay, A. (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends in Immunology, 25, 4-7. Ford, E.S., Zhao, G. & Li, C. (2010) Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. Journal of the American College of Cardiology, 55, 1310-1317. Bergamini, C.M., Gambetti, S., Dondi, A. et al. (2004) Oxygen, reactive oxygen species and tissue damage. Current Pharmaceutical Design, 10, 1611-1626. The DECODE Study Group (2003) Is the current definition for diabetes relevant to mor- tality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care, 26, 688-696. Festa, A., D'Agostino, R. Jr, Howard, G. et al. (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 102, 42-47. Shaw, J.E., Zimmet, P.Z., de Courten, M. et al. (1999) Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritus? Diabetes Care, 22, 399-402. The DECODE Study Group. European Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet, 354, 617-621. de Vegt, F., Dekker, J.M., Jager, A. et al. (2001) Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population; The Hoorn study. JAMA, 285, 2109-2113. Ning, F., Tuomilehto, J., Pyorala, K. et al. (2010) Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care, 33, 2211-2216. Abbasi, A., Corpeleijn, E., Gansevoort, R.T. et al. (2014) Circulating peroxiredoxin 4 and type 2 diabetes risk: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia, 57, 1842-1849. Ding, Y., Yamada, S., Wang, K.Y. et al. (2010) Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice. Antioxidants & Redox Signaling, 13, 1477-1490. Al-Masri, A., El Eter, E., Tayel, S. et al. (2014) Differential associations of circulating peroxiredoxins levels with indicators of glycemic control in type 2 diabetes mellitus. European Review for Medical and Pharmacological Sciences, 18, 710-716. Abbasi, A., Corpeleijn, E., Postmus, D. et al. (2012) Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all-cause mortality. Journal of the American Heart Association, 1, e002956. Wood, Z.A., Schroder, E., Harris, J.R. et al. (2003) Structure, mechanism and regulation of peroxiredoxins. Trends in Biochemical Sciences, 28, 32-40. Ascaso, J., Pardo, S., Real, J.T. et al. (2003) Diagnosing insulin resistance b;y simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care, 26, 3320-3325. Valko, M., Leibfritz, D., Moncol, J. et al. (2007) Free radicals and antioxidants in normal physiological functions and human disease. International Journal of Biochemistry & Cell Biology, 39, 44-84. Choi, S.W., Bensie, I., Ma, S.W. et al. (2008) Acute hyperglycemia and oxidative stress: direct cause and effect? Free Radical Biology and Medicine, 4, 1217-1231. Rabilloud, T., Heller, M., Gasnier, F. et al. (2002) Proteomics analysis of cellular response to oxidative stress: evidence for in vivo over- oxidation of peroxiredoxins at their active site. Journal of Biological Chemistry, 277, 19396-19401. Ascaso, J.F., Romero, P., Real, T.J. et al. (2001) Insulin resistance quantification by fasting insulin plasma values and HOMA index in non diabetic population. Medicina Clinica, 117, 530-533. Fujii, J. & Ikeda, Y. (2002) Advances in our understanding of peroxiredoxin, amultifunctional, mammalian redox protein. Redox Report, 7, 123-130. Gerrits, E.G., Alkhalaf, A., Landman, G.W. et al. (2014) Serum peroxiredoxin 4: a marker of oxidative stress associated with mortality in type 2 diabetes (ZODIAC-28). PLoS One, 9, e89719. Wen, C.P., Cheng, T.Y., Tsai, S.P. et al. (2005) Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care, 28, 2756-2761. Levitan, E.B., Song, Y., Ford, E.S. et al. (2004) Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Archives of Internal Medicine, 164, 2147-2155. 2007; 39 2010; 33 2010; 55 2004; 164 2001; 285 2010; 13 2004; 25 2010; 123 2002; 7 2002; 277 1999; 22 2008; 4 2005; 28 2004; 10 2015; 48 2012; 1 2000; 102 2003; 26 2014; 57 2003; 28 2014; 19 2014; 18 1999; 354 2014; 9 2014; 142 2001; 117 e_1_2_9_11_1 e_1_2_9_10_1 e_1_2_9_13_1 e_1_2_9_12_1 Al‐Masri A. (e_1_2_9_27_1) 2014; 18 e_1_2_9_15_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_20_1 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_24_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 |
| References_xml | – reference: Choi, S.W., Bensie, I., Ma, S.W. et al. (2008) Acute hyperglycemia and oxidative stress: direct cause and effect? Free Radical Biology and Medicine, 4, 1217-1231. – reference: Abbasi, A., Corpeleijn, E., Gansevoort, R.T. et al. (2014) Circulating peroxiredoxin 4 and type 2 diabetes risk: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia, 57, 1842-1849. – reference: Levitan, E.B., Song, Y., Ford, E.S. et al. (2004) Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Archives of Internal Medicine, 164, 2147-2155. – reference: Tavender, T.J. & Bulleid, N.J. (2010) Peroxiredoxin IV protects cells from oxidative stress by removing H2O2 produced during disulphide formation. Journal of Cell Science, 123, 2672-2679. – reference: Wood, Z.A., Schroder, E., Harris, J.R. et al. (2003) Structure, mechanism and regulation of peroxiredoxins. Trends in Biochemical Sciences, 28, 32-40. – reference: Rabilloud, T., Heller, M., Gasnier, F. et al. (2002) Proteomics analysis of cellular response to oxidative stress: evidence for in vivo over- oxidation of peroxiredoxins at their active site. Journal of Biological Chemistry, 277, 19396-19401. – reference: Valko, M., Leibfritz, D., Moncol, J. et al. (2007) Free radicals and antioxidants in normal physiological functions and human disease. International Journal of Biochemistry & Cell Biology, 39, 44-84. – reference: Gerrits, E.G., Alkhalaf, A., Landman, G.W. et al. (2014) Serum peroxiredoxin 4: a marker of oxidative stress associated with mortality in type 2 diabetes (ZODIAC-28). PLoS One, 9, e89719. – reference: Arancibia, C., Galgani, J., Valderas, J.P. et al. (2014) Evaluation of serum insulin levels after an oral glucose load for the diagnosis of insulin resistance. Revista Medica de Chile, 142, 1106-1112. – reference: Ning, F., Tuomilehto, J., Pyorala, K. et al. (2010) Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes Care, 33, 2211-2216. – reference: de Vegt, F., Dekker, J.M., Jager, A. et al. (2001) Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population; The Hoorn study. JAMA, 285, 2109-2113. – reference: Abbasi, A., Corpeleijn, E., Postmus, D. et al. (2012) Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all-cause mortality. Journal of the American Heart Association, 1, e002956. – reference: The DECODE Study Group (2003) Is the current definition for diabetes relevant to mor- tality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care, 26, 688-696. – reference: Ascaso, J.F., Romero, P., Real, T.J. et al. (2001) Insulin resistance quantification by fasting insulin plasma values and HOMA index in non diabetic population. Medicina Clinica, 117, 530-533. – reference: The DECODE Study Group. European Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet, 354, 617-621. – reference: Wen, C.P., Cheng, T.Y., Tsai, S.P. et al. (2005) Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care, 28, 2756-2761. – reference: El Eter, E., Al Masri, A., Habib, S., Al Zamil, H., Al Hersi, A., Al Hussein, F. & Al Omran, M. (2014) Novel links among peroxiredoxins, endothelial dysfunction, and severity of atherosclerosis in type 2 diabetic patients with peripheral atherosclerotic disease. Cell Stress and Chaperones, 19, 173-81. – reference: Shaw, J.E., Zimmet, P.Z., de Courten, M. et al. (1999) Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritus? Diabetes Care, 22, 399-402. – reference: Ding, Y., Yamada, S., Wang, K.Y. et al. (2010) Overexpression of peroxiredoxin 4 protects against high-dose streptozotocin-induced diabetes by suppressing oxidative stress and cytokines in transgenic mice. Antioxidants & Redox Signaling, 13, 1477-1490. – reference: Ford, E.S., Zhao, G. & Li, C. (2010) Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. Journal of the American College of Cardiology, 55, 1310-1317. – reference: Dandona, P., Aljada, A. & Bandyopadhyay, A. (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends in Immunology, 25, 4-7. – reference: El Eter, E. & Al-Masri, A. (2015) Peroxiredoxin isoforms are associated with cardiovascular risk factors in type 2 diabetes mellitus. Brazilian Journal of Medical and Biological Research, 48, 465-469. – reference: Ascaso, J., Pardo, S., Real, J.T. et al. (2003) Diagnosing insulin resistance b;y simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care, 26, 3320-3325. – reference: Al-Masri, A., El Eter, E., Tayel, S. et al. (2014) Differential associations of circulating peroxiredoxins levels with indicators of glycemic control in type 2 diabetes mellitus. European Review for Medical and Pharmacological Sciences, 18, 710-716. – reference: Bergamini, C.M., Gambetti, S., Dondi, A. et al. (2004) Oxygen, reactive oxygen species and tissue damage. Current Pharmaceutical Design, 10, 1611-1626. – reference: Fujii, J. & Ikeda, Y. (2002) Advances in our understanding of peroxiredoxin, amultifunctional, mammalian redox protein. Redox Report, 7, 123-130. – reference: Festa, A., D'Agostino, R. Jr, Howard, G. et al. (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 102, 42-47. – volume: 28 start-page: 32 year: 2003 end-page: 40 article-title: Structure, mechanism and regulation of peroxiredoxins publication-title: Trends in Biochemical Sciences – volume: 26 start-page: 3320 year: 2003 end-page: 3325 article-title: Diagnosing insulin resistance b;y simple quantitative methods in subjects with normal glucose metabolism publication-title: Diabetes Care – volume: 164 start-page: 2147 year: 2004 end-page: 2155 article-title: Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta‐analysis of prospective studies publication-title: Archives of Internal Medicine – volume: 123 start-page: 2672 year: 2010 end-page: 2679 article-title: Peroxiredoxin IV protects cells from oxidative stress by removing H2O2 produced during disulphide formation publication-title: Journal of Cell Science – volume: 25 start-page: 4 year: 2004 end-page: 7 article-title: Inflammation: the link between insulin resistance, obesity and diabetes publication-title: Trends in Immunology – volume: 354 start-page: 617 year: 1999 end-page: 621 article-title: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe publication-title: Lancet – volume: 13 start-page: 1477 year: 2010 end-page: 1490 article-title: Overexpression of peroxiredoxin 4 protects against high‐dose streptozotocin‐induced diabetes by suppressing oxidative stress and cytokines in transgenic mice publication-title: Antioxidants & Redox Signaling – volume: 285 start-page: 2109 year: 2001 end-page: 2113 article-title: Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population; The Hoorn study publication-title: JAMA – volume: 1 start-page: e002956 year: 2012 article-title: Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all‐cause mortality publication-title: Journal of the American Heart Association – volume: 10 start-page: 1611 year: 2004 end-page: 1626 article-title: Oxygen, reactive oxygen species and tissue damage publication-title: Current Pharmaceutical Design – volume: 142 start-page: 1106 year: 2014 end-page: 1112 article-title: Evaluation of serum insulin levels after an oral glucose load for the diagnosis of insulin resistance publication-title: Revista Medica de Chile – volume: 4 start-page: 1217 year: 2008 end-page: 1231 article-title: Acute hyperglycemia and oxidative stress: direct cause and effect? publication-title: Free Radical Biology and Medicine – volume: 277 start-page: 19396 year: 2002 end-page: 19401 article-title: Proteomics analysis of cellular response to oxidative stress: evidence for in vivo over‐ oxidation of peroxiredoxins at their active site publication-title: Journal of Biological Chemistry – volume: 18 start-page: 710 year: 2014 end-page: 716 article-title: Differential associations of circulating peroxiredoxins levels with indicators of glycemic control in type 2 diabetes mellitus publication-title: European Review for Medical and Pharmacological Sciences – volume: 22 start-page: 399 year: 1999 end-page: 402 article-title: Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritus? publication-title: Diabetes Care – volume: 19 start-page: 173 year: 2014 end-page: 81 article-title: Novel links among peroxiredoxins, endothelial dysfunction, and severity of atherosclerosis in type 2 diabetic patients with peripheral atherosclerotic disease publication-title: Cell Stress and Chaperones – volume: 57 start-page: 1842 year: 2014 end-page: 1849 article-title: Circulating peroxiredoxin 4 and type 2 diabetes risk: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study publication-title: Diabetologia – volume: 48 start-page: 465 year: 2015 end-page: 469 article-title: Peroxiredoxin isoforms are associated with cardiovascular risk factors in type 2 diabetes mellitus publication-title: Brazilian Journal of Medical and Biological Research – volume: 55 start-page: 1310 year: 2010 end-page: 1317 article-title: Pre‐diabetes and the risk for cardiovascular disease: a systematic review of the evidence publication-title: Journal of the American College of Cardiology – volume: 117 start-page: 530 year: 2001 end-page: 533 article-title: Insulin resistance quantification by fasting insulin plasma values and HOMA index in non diabetic population publication-title: Medicina Clinica – volume: 7 start-page: 123 year: 2002 end-page: 130 article-title: Advances in our understanding of peroxiredoxin, amultifunctional, mammalian redox protein publication-title: Redox Report – volume: 28 start-page: 2756 year: 2005 end-page: 2761 article-title: Increased mortality risks of pre‐diabetes (impaired fasting glucose) in Taiwan publication-title: Diabetes Care – volume: 9 start-page: e89719 year: 2014 article-title: Serum peroxiredoxin 4: a marker of oxidative stress associated with mortality in type 2 diabetes (ZODIAC‐28) publication-title: PLoS One – volume: 33 start-page: 2211 year: 2010 end-page: 2216 article-title: Cardiovascular disease mortality in Europeans in relation to fasting and 2‐h plasma glucose levels within a normoglycemic range publication-title: Diabetes Care – volume: 26 start-page: 688 year: 2003 end-page: 696 article-title: Is the current definition for diabetes relevant to mor‐ tality risk from all causes and cardiovascular and noncardiovascular diseases? publication-title: Diabetes Care – volume: 102 start-page: 42 year: 2000 end-page: 47 article-title: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS) publication-title: Circulation – volume: 39 start-page: 44 year: 2007 end-page: 84 article-title: Free radicals and antioxidants in normal physiological functions and human disease publication-title: International Journal of Biochemistry & Cell Biology – ident: e_1_2_9_20_1 doi: 10.4067/S0034-98872014000900003 – ident: e_1_2_9_19_1 doi: 10.1371/journal.pone.0089719 – ident: e_1_2_9_23_1 doi: 10.1001/archinte.164.19.2147 – ident: e_1_2_9_6_1 doi: 10.2337/dc09-2328 – ident: e_1_2_9_14_1 doi: 10.1242/jcs.067843 – ident: e_1_2_9_22_1 doi: 10.1016/S0025-7753(01)72168-9 – ident: e_1_2_9_3_1 doi: 10.1001/jama.285.16.2109 – ident: e_1_2_9_2_1 doi: 10.2337/diacare.22.3.399 – ident: e_1_2_9_4_1 doi: 10.1016/S0140-6736(98)12131-1 – ident: e_1_2_9_26_1 doi: 10.1590/1414-431X20144142 – ident: e_1_2_9_8_1 doi: 10.1016/j.freeradbiomed.2007.12.005 – ident: e_1_2_9_18_1 doi: 10.1161/JAHA.112.002956 – ident: e_1_2_9_28_1 doi: 10.1007/s00125-014-3278-9 – ident: e_1_2_9_7_1 doi: 10.1016/j.jacc.2009.10.060 – ident: e_1_2_9_24_1 doi: 10.2337/diacare.28.11.2756 – ident: e_1_2_9_10_1 doi: 10.1161/01.CIR.102.1.42 – ident: e_1_2_9_21_1 doi: 10.2337/diacare.26.12.3320 – ident: e_1_2_9_25_1 doi: 10.1007/s12192-013-0442-y – ident: e_1_2_9_15_1 doi: 10.1179/135100002125000352 – ident: e_1_2_9_11_1 doi: 10.2174/1381612043384664 – ident: e_1_2_9_13_1 doi: 10.1016/j.biocel.2006.07.001 – ident: e_1_2_9_5_1 doi: 10.2337/diacare.26.3.688 – ident: e_1_2_9_17_1 doi: 10.1089/ars.2010.3137 – ident: e_1_2_9_16_1 doi: 10.1074/jbc.M106585200 – ident: e_1_2_9_12_1 doi: 10.1016/S0968-0004(02)00003-8 – volume: 18 start-page: 710 year: 2014 ident: e_1_2_9_27_1 article-title: Differential associations of circulating peroxiredoxins levels with indicators of glycemic control in type 2 diabetes mellitus publication-title: European Review for Medical and Pharmacological Sciences – ident: e_1_2_9_9_1 doi: 10.1016/j.it.2003.10.013 |
| SSID | ssj0005807 |
| Score | 2.2268155 |
| Snippet | Summary
Background
Peroxiredoxin 4 is a part of endogen antioxidant system and its levels are elevated in oxidative stress conditions. Its levels are... Peroxiredoxin 4 is a part of endogen antioxidant system and its levels are elevated in oxidative stress conditions. Its levels are positively associated with... Summary Background Peroxiredoxin 4 is a part of endogen antioxidant system and its levels are elevated in oxidative stress conditions. Its levels are... Background Peroxiredoxin 4 is a part of endogen antioxidant system and its levels are elevated in oxidative stress conditions. Its levels are positively... |
| SourceID | proquest pubmed crossref wiley istex |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 551 |
| SubjectTerms | Adult Body Size Case-Control Studies Glucose Tolerance Test Humans Insulin Resistance Metabolic Syndrome Middle Aged Obesity - blood Peroxiredoxins - blood Prediabetic State - blood |
| Title | Increased peroxiredoxin 4 levels in patients with prediabetes compared to normal glucose tolerance subjects |
| URI | https://api.istex.fr/ark:/67375/WNG-HK5M1H2D-Z/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcen.13135 https://www.ncbi.nlm.nih.gov/pubmed/27303935 https://www.proquest.com/docview/1822920670 https://www.proquest.com/docview/1823907835 https://www.proquest.com/docview/1827889298 |
| Volume | 85 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9RAFD6UCuKLWq9pq4wi4kuWXGaSLD5JLy7K7oNYLCIMczmBsku2bHZh6a_vnMkkWqkivoXkDMztzHyZ851vAN7kArmm7B5Dare8tCpWODaxViIxmNVWeYmN6ayYnPFP5-J8B973uTCdPsRw4Eae4ddrcnCl21-c3GAzSvM0pwRz4moRIPryUzpKhFTpnDKni4IHVSFi8Qwlb-xFd6hbt7cBzZu41W88pw_gR1_ljm8yH23WemSuflNz_M82PYT7AZCyD90M2oMdbB7B3WkIuT-GuVtBiLiOlpGm-PaCFEa3Fw3jbEGEo5a556DO2jI61mWXK-yPdFnPcWfrJWsIHy9YYMm7Nwukaz2QtRtNx0HtEzg7Pfl6NInDDQ2xoYhpnKnalrqqE6HLlFsHPRQvEkTFuVtJxihwnFkulMpSniprElXnNaUCa6OyqsL8Kew2ywafA9MOiFp0-K1OkVcOSOhCVcqVtjZLCoMRvOvHSpogX063aCxk_xvjOk_6zovg9WB62Wl23Gb01g_4YKFWcyK5lUJ-m32Uk89imk6yY_k9gsN-Rsjg361MSSeflO-TCF4Nn51nUrhFNbjceJt8TFFS8VebsqocRK0ieNbNtqFCDlj6xGnXcj9n_twWeXQy8w_7_256APcc9is6XuIh7K5XG3zh8NVav_SOdA11oSEU |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zi9RAEC7WXVBfvI_oqq2I-JIhR3eSAV9kD6O7Mw-yi4sgTR8VWGbILJMZGPz1dnUOXVlFfAtJNfRR1f2ljq8BXqcCuabqHkNstzy3KlQ4NqFWIjKYVFZ5io3JNCtP-aczcbYF7_pamJYfYnC4kWX4_ZoMnBzSv1i5wXoUp3EqrsEO3ehNzPn7n3-SR4muWDql2uks4x2vEOXxDE0vnUY7NLGbq6DmZeTqj57D2_Ct73SbcTIbrVd6ZL7_xuf4v6O6A7c6TMret0p0F7awvgfXJ13U_T7M3CZCuetoGdGKb86JZHRzXjPO5pRz1DD33BG0Now8u-xiib1Xl_Vp7my1YDVB5DnrEuXdmznSzR7ImrUmj1DzAE4PD072yrC7pCE0FDQNE1XZXBdVJHQec-vQh-JZhKg4d5vJGAWOE8uFUknMY2VNpKq0ompgbVRSFJg-hO16UeNjYNphUYsOwlUx8sJhCZ2pQrnW1iZRZjCAt_1iSdMxmNNFGnPZ_8m4yZN-8gJ4NYhetLQdVwm98Ss-SKjljPLcciG_TD_I8khM4jLZl18D2O1VQnYm3siYqPKJ_D4K4OXw2RknRVxUjYu1l0nHFCgVf5XJi8Kh1CKAR626DR1y2NLXTruRe6X581jk3sHUPzz5d9EXcKM8mRzL44_To6dw00HBrE1T3IXt1XKNzxzcWunn3qp-AHB3JTA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1baxQxFD7UFoov1rujVaOI-DLLXJK54JN0u67WXUQsFimETHIGyi6zy84uLP315mQuWqkivg0zJ5DLOck35_IF4FUskBdU3aOJ7ZanRvkKc-0XSgQao9IoR7ExmSbjU_7xTJztwNuuFqbhh-gdbmQZbr8mA1-a8hcj11gNwjiMxQ3Y40mQ070Nwy8_uaNEWysdU-l0kvCWVojSePqmVw6jPZrX7XVI8ypwdSfP6ADOuz43CSezwWZdDPTlb3SO_zmo23CrRaTsXaNCd2AHq7uwP2lj7vdgZrcQylxHw4hUfHtBFKPbi4pxNqeMo5rZ55aetWbk12XLFXY-XdYlubP1glUEkOesTZO3b-ZI93ogqzcF-YPq-3A6Ov56NPbbKxp8TSFTP1KlSYusDESRhtxY7KHsWiAqzu1WkqPAPDJcKBWFPFRGB6qMS6oFLrSKsgzjB7BbLSp8BKywSNSgBXBliDyzSKJIVKZsa2OiINHowZturaRu-cvpGo257P5j7ORJN3kevOxFlw1px3VCr92C9xJqNaMst1TIb9P3cnwiJuE4GsrvHhx2GiFbA69lSET5RH0fePCi_2xNk-ItqsLFxsnEOYVJxV9l0iyzGDXz4GGjbX2HLLJ0ldN25E5n_jwWeXQ8dQ-P_130Oex_Ho7kpw_Tkydw0-LApMlRPITd9WqDTy3WWhfPnE39AOdDI98 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+peroxiredoxin+4+levels+in+patients+with+prediabetes+compared+to+normal+glucose+tolerance+subjects&rft.jtitle=Clinical+endocrinology+%28Oxford%29&rft.au=Gateva%2C+Antoaneta&rft.au=Assyov%2C+Yavor&rft.au=Velikova%2C+Tsvetelina&rft.au=Kamenov%2C+Zdravko&rft.date=2016-10-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0300-0664&rft.eissn=1365-2265&rft.volume=85&rft.issue=4&rft.spage=551&rft_id=info:doi/10.1111%2Fcen.13135&rft.externalDBID=NO_FULL_TEXT&rft.externalDocID=4193562641 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-0664&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-0664&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-0664&client=summon |